Biotron Limited · ASX:BIT
Biotron — Investor Presentation (November 2022)
12 slides from Biotron's investor presentation, November 2022
Slide 1: Investor Update
BIOTRON LIMITED (ASX:BIT) Investor Update November 2022
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain forward‐looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited (ACN 086 399 144) and certain of the plans and objectives of its management. These statements are statements t
Slide 3: Biotron Overview
Biotron Overview • Clinical stage company with portfolio of small molecule drugs targeting viral diseases with major health problems: • HIV-1 , COVID-19, Hepatitis B virus and others • Unique approach to tackling virus infections • New class of anti-viral drugs that work in two ways: • Stop replicat
Slide 4: Key Achievements in 2022
Key Achievements in 2022 • Completed enrolment of two Phase 2 HIV-1 clinical trials that build on positive results in previous clinical studies • Results expected mid-2023 • These studies are key to positioning of BIT225 for partnering • Demonstrated that BIT225 stops replication of SARS-CoV-2 and p
Slide 5: HIV-1 Clinical Program Update
HIV-1 Clinical Program Update • Two Phase 2 HIV-1 clinical trials currently in progress at sites in Sydney, Australia (Holdsworth House, East Sydney Doctors and St Vincent’s Hospital, Darlinghurst) and in Thailand (Bangkok and Chiang Mai) • Both trials are fully recruited • Results expected mid-2023
Slide 6: HIV-1 Market Opportunity
HIV-1 Market Opportunity • In 2021, despite availability of antiretroviral drugs (ART) - • Over 38.4 million people globally were living with HIV • 1.5 million newly infected with the virus • An estimated 650,000 people died from AIDS-related illnesses. • The global HIV drug market in 2021 was estim
Slide 7: SARS-CoV-2/COVID-19 Program Update
SARS-CoV-2/COVID-19 Program Update • BIT225 has demonstrated ability to prevent COVID-19, reduce virus and stop the cytokine storm in a relevant, robust, industry-recognised animal model of disease* • A human COVID-19 study is in progress as a sub-study in Thailand in one of the current HIV-1 Phase
Slide 8: Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs
Ongoing Need for SARS-CoV-2/COVID-19 Anti-Viral Drugs • Vaccines remain central to control of the pandemic but there is an unmet need for effective drugs to treat COVID • Uncertain global pandemic outlook • On-going risk of emergence of new SARS-CoV-2 variants • At risk populations e.g. immunodefici
Slide 9: BIT225 Opportunity Summary
BIT225 Opportunity Summary • BIT225 is a very important clinical asset for Biotron • Previous positive clinical trial data have significantly de-risked the program • Clear clinical development program designed to demonstrate to regulators and pharma how the drug may be used to improve health outcome
Slide 10: Outlook for 2023
Outlook for 2023 • 2023 will be an important year for this Company • Results of three Phase 2 clinical trials expected in mid-2023 • Two Phase 2 HIV-1 clinical trials • Includes the COVID-19 sub-study that is in progress • New Phase 2 COVID clinical trial (subject to funding) • These will be key val
Slide 11: Financial Information
Financial Information Key Financial Metrics Ticker Code ASX: BIT Share Price (10/11/2022) A $0.035 Market Cap A $25 million 12 Month Trading Range A $0.033 – 0.111 A $0.68 million Cash Position (09/2022) + Anticipate receipt of R&D Tax refund of ~$1.4 m before end 2022 Board Michael Hoy Non-executiv
Slide 12: BIOTRON LIMITED (ASX:BIT)
BIOTRON LIMITED (ASX:BIT) Michelle Miller Managing Director mmiller@biotron.com.au www.biotron.com.au +61 412313329